Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL3628 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL18593671 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL3629 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14107274 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL17813675 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL6146 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL153952 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL19884331 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22450052 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22022258 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149377-A1 | PHARMACEUTICAL METHODS | ELEVAR THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149377-A1 | PHARMACEUTICAL METHODS | ELEVAR THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11007271-B2 | Anticancer drug conjugates | Ariel Scientific Innovations Ltd. (IL) | 2021-05-18 | — | — | US | disclosed |
| US-20210069147-A1 | PHARMACEUTICAL COMBINATION AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-03-11 | — | — | US | disclosed |
| US-20210024944-A1 | METHOD OF PRODUCING ALKALOID | AJINOMOTO CO., INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20200215196-A1 | MINIMALLY TOXIC PRODRUGS | LIFE SCIENCES RESEARCH PARTNERS VZW (BE) | 2020-07-09 | — | — | US | disclosed |
| US-10564162-B2 | Predictive biomarkers | BIONOMICS LIMITED (AU) | 2020-02-18 | — | — | US | disclosed |
| US-20190224328-A1 | ANTICANCER DRUG CONJUGATES | Ariel Scientific Innovations Ltd. (IL) | 2019-07-25 | — | — | US | disclosed |
| US-20190175740-A1 | MINIMALLY TOXIC PRODRUGS | COBIORES NV (BE) | 2019-06-13 | — | — | US | disclosed |
| US-20170135980-A1 | PREDICTING RESPONSE TO CANCER THERAPY | BIONOMICS LIMITED (AU) | 2017-05-18 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160058880-A1 | MINIMALLY TOXIC PRODRUGS | COBIORES NV (BE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058880-A1 | MINIMALLY TOXIC PRODRUGS | COBIORES NV (BE) | 2016-03-03 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-9173898-B2 | Methods of treating giardiasis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173898-B2 | Methods of treating giardiasis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140148398-A1 | METHODS OF TREATING GIARDIASIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148398-A1 | METHODS OF TREATING GIARDIASIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170135980-A1 | PREDICTING RESPONSE TO CANCER THERAPY | RPTOR, MTOR, PIK3CA | TUBB4A 1234/4885TUBB 1672/4885TUBA3C 2825/4885 |
| US-20200215196-A1 | MINIMALLY TOXIC PRODRUGS | ALG8, LNPEP, ALG1 | TUBB4A 2808/4885TUBB 2921/4885TUBA3C 2915/4885 |
| US-20190224328-A1 | ANTICANCER DRUG CONJUGATES | BCR, MCL1, TP53 | TUBB4A 122/4885TUBB 55/4885TUBA3C 186/4885 |
| US-20230149377-A1 | PHARMACEUTICAL METHODS | TUBB1, TUBB, TUBB3 | TUBB4A 14/4885TUBB 2/4885TUBA3C 11/4885 |
| US-20160058880-A1 | MINIMALLY TOXIC PRODRUGS | ALG8, ALG1, LNPEP | TUBB4A 2233/4885TUBB 2316/4885TUBA3C 2553/4885 |
| US-20210069147-A1 | PHARMACEUTICAL COMBINATION AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | TUBB4A 29/4885TUBB 49/4885TUBA3C 37/4885 |
| US-20140148398-A1 | METHODS OF TREATING GIARDIASIS | GGH, GYS2, TUBB | TUBB4A 32/4885TUBB 3/4885TUBA3C 31/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | TUBB4A 3825/4885TUBB 3451/4885TUBA3C 3136/4885 |
| US-20190175740-A1 | MINIMALLY TOXIC PRODRUGS | ALG8, ALG1, LNPEP | TUBB4A 2233/4885TUBB 2316/4885TUBA3C 2553/4885 |
| US-11007271-B2 | Anticancer drug conjugates | BCR, MCL1, TP53 | TUBB4A 122/4885TUBB 55/4885TUBA3C 186/4885 |
| US-10564162-B2 | Predictive biomarkers | MMP10, SHBG, MMP11 | TUBB4A 774/4885TUBB 557/4885TUBA3C 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.